Eli Lilly Market Cap 2010-2023 | LLY

Eli Lilly market cap history and chart from 2010 to 2023. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Eli Lilly market cap as of September 20, 2023 is $540.76B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $540.757B $28.541B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $425.104B 44.90
Johnson & Johnson (JNJ) United States $423.398B 15.69
Merck (MRK) United States $272.301B 38.19
AbbVie (ABBV) United States $271.129B 12.16
Novartis AG (NVS) Switzerland $219.548B 15.62
AstraZeneca (AZN) United Kingdom $210.662B 19.04
Pfizer (PFE) United States $189.817B 6.98
Sanofi (SNY) $139.368B 12.46
Innoviva (INVA) United States $0.831B 9.45